Released May 6, 2025, before the open
10-Q filed May 6, 2025, 36 days after period end · 0000950170-25-063956
Q1 2025 · 10-Q
Revenue$193.65M$193.65M +2.7% vs Q1 2024−10.2% vs Q4 2024
Net Income-$53.09M-$53.09M N/M vs Q1 2024N/M vs Q4 2024
EPS Diluted-$1.35-$1.35 N/M vs Q1 2024no prior Q4 2024 on file
Gross Profit$121,619,000−4.4%
Operating Income-$48,873,000N/M
Operating Cash Flow-$18,391,000N/M
Free Cash Flowderived-$25,127,000N/M
Margins · derived
Gross margin62.8%−4.7 pt vs Q1 2024
Operating margin-25.2%−9.7 pt vs Q1 2024
Net margin-27.4%−8.3 pt vs Q1 2024
What the release said
The release
Same quarter
| Metric | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 |
|---|---|---|---|---|
| Revenue | $193.65M | $188.61M | $175.20M | $106.42M |
| Net Income | -$53.09M | -$36.02M | -$60.94M | -$4.46M |
| EPS Diluted | -$1.35 | -$0.95 | -$1.71 | -$0.22 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Orthofix Medical Inc. · CIK 884624 · Engraved from SEC EDGAR